Clinical trials: IBS
IBS - Irritable Bowel Syndrome
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
The aim of the study is to demonstrate a beneficial effect in reducing symptoms that negatively affect the quality of life of IBS patients, and to demonstrate a positive effect on inflammatory and intestinal function markers.
- Trial name
- NCT05990764
- Testing
- Probiotic, Prebiotic, Polyphenol-rich Extracts, Probiotic, Prebiotic
- Where
- Poland
- Volunteers
- 48 people
- Sponsor
- AronPharma Sp. z o. o.
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation
This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.
- Trial name
- YKP (NCT02082457)
- Testing
- YKP10811 5mg, YKP10811 20mg
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- SK Chemicals Co., Ltd.
Irritable Bowel Syndrome (IBS)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- RESTORE (NCT01844180)
- Testing
- ONO-2952
- Where
- 48 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ono Pharma USA Inc
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Coronary Artery Disease
A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
A prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared…
- Trial name
- IRONMAN-II (NCT05206084)
- Testing
- Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS), Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
- Where
- China
- Volunteers
- 518 people
- Sponsor
- Biotyx Medical (Shenzhen) Co., Ltd.
Constipation
Open Label Tolerability Study of ISOThrive Prebiotic Nectar (MIMO) in Subjects With Constipation
The purpose and efficacy endpoint of this study is to assess whether subjects with constipation predominant irritable bowel syndrome (IBS-C) or chronic Idiopathic constipation (CIC) tolerate ISOThrive.
- Trial name
- NCT04677634
- Testing
- ISOThrive Prebiotic Nectar
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- ISOThrive Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C
Irritable bowel syndrome (IBS) is a common functional bowel disorder that imposes a considerable burden on health-related quality of life (QOL) worldwide.
- Trial name
- RELAX (NCT05240521)
- Testing
- ARM A, ARM B
- Where
- 4 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Devintec Sagl
Diarrhea-predominant Irritable Bowel Syndrome
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and…
- Trial name
- NCT03977155
- Testing
- BOS-589
- Where
- 58 sites in United States
- Volunteers
- 133 people
- Sponsor
- Boston Pharmaceuticals
IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease)
Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, often associated with impaired intestinal barrier function, low-grade…
- Conditions
- IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease), Gut Health
- Trial name
- NCT07699926
- Testing
- Postbiotic supplementation
- Where
- Malaysia
- Volunteers
- 55 people
- Sponsor
- My Myracle Sdn.Bhd
Irritable Bowel Syndrome (IBS)
Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients
The study is a randomised, placebo-controlled, double-blind parallel study in IBS patients. A total of 60 adult patients diagnosed with IBS-C, -D or -A/M according to Rome IV criteria will be included.
- Trial name
- NCT02875847
- Testing
- HMO1, HMO2, Dextropur
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Glycom A/S
Diarrhea Predominant Irritable Bowel Syndrome
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.
- Trial name
- NCT01100684
- Testing
- Asimadoline
- Where
- 142 sites in United States
- Volunteers
- 611 people
- Sponsor
- Tioga Pharmaceuticals
Irritable Colon
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
- Trial name
- NCT00101985
- Testing
- talnetant
- Where
- 135 sites in United States, Australia and 8 more
- Volunteers
- 741 people
- Sponsor
- GlaxoSmithKline
GLP-1, Adults
Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication
This is a single-arm, open-label clinical trial involving 100 participants who will undergo a total participation period of 12 weeks.
- Trial name
- NCT07130396
- Testing
- Multivitamin and a Probiotic
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility, safety and efficacy of iron resorbable stent…
- Trial name
- NCT04291222
- Testing
- Iron biocorrodable coronary scaffold system
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel…
- Conditions
- IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
- Trial name
- NCT07089420
- Testing
- ALPCO Calprotectin CLIA
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
Rheumatoid Arthritis, Diabetic Neuropathy
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital…
- Conditions
- Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
- Trial name
- NCT05573685
- Testing
- DiNaMo Study App
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Click Therapeutics, Inc.
IBS - Irritable Bowel Syndrome
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)
The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in…
- Trial name
- NCT05509725
- Testing
- Probiotic formulation
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome-IBS
Evaluate the Safety of Linaclotide in IBS-C Patients in China
This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for…
- Trial name
- Liberty (NCT04462900)
- Where
- 29 sites in China
- Volunteers
- 3,028 people
- Sponsor
- AstraZeneca